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The glutamate system dysfunctions present in schizophrenia raise new questions about 
possible glutamatergic actions of the atypical antipsychotic clozapine. While clozapine has 
been shown to partially substitute for the discriminative stimulus of the glutamate agonist 
N-methyl D-aspartate (NMDA) in rats, NMDA discrimination has not previously been 
established in mice. The present study was designed to explore the possible role of NMDA 
activity in clozapine’s discriminative stimulus. Two groups of C57BL/6 mice were trained 
to discriminate either 2.5 mg/kg CLZ from vehicle or 30 mg/kg NMDA from vehicle in a 
standard two-lever drug discrimination task. NMDA drug discrimination was successfully 
 v
   
 vi
established in C57BL/6 mice. While NMDA did not substitute for clozapine, clozapine 
partially substituted for NMDA at the 0.625 mg/kg dose, demonstrating an asymmetrical 
relationship between clozapine’s and NMDA’s discriminative stimuli. Dose combination 
tests further investigated this relationship. It was found that 0.625 mg/kg CLZ + 30 mg/kg 
NMDA produced partial substitution (61.82% DLR), while 0.625 mg/kg CLZ + 56 mg/kg 
NDMA full substitution (92.82% DLR) in CLZ-trained mice. In addition, combination 
testing with 10 mg/kg NMDA + 2.5 mg/kg CLZ and 10 mg/kg NMDA + 5.0 mg/kg CLZ 
produced full substitution in NMDA-trained mice ((80.04% DLR and 100% DLR, 
respectively). Finally, it was found that the α1- adrenoreceptor antagonist prazosin fully 
substituted for both CLZ (3.0 mg/kg = 92.20% DLR) and NMDA (1.0 mg/kg = 98.77% 
DLR and 3.0 mg/kg = 99.62% DLR). These findings suggest that interactions between 
clozapine’s and NMDA’s discriminative stimuli may involve antagonism of α1- 
adrenoreceptors, but further research of other mechanisms including serotonergic, 
histaminergic, and cholinergic receptor activity or metabolic interactions is needed. 
Finally, these initial finding suggest that that drugs active at glutamatergic receptors may 




Schizophrenia is a debilitating brain disorder that affects approximately 0.7% of the 
world’s population (Saha, Chant, Welham, & McGrath, 2005). The disorder is complex 
with a range of symptoms that manifest diversely in the affected population. Schizophrenia 
occurs equally between the sexes and has an onset in early adulthood with rare cases 
occurring in late adolescence. While recent studies link specific genes to schizophrenia 
(Owen, Craddock, & O'Donovan, 2005) the genetic component is not absolute but rather 
may be an indicator of the predisposition for the disorder (Gottesman & Gould, 2003) 
suggesting that environmental and/or ecological factors may play an important role in the 
etiology of schizophrenia. Schizophrenia is a progressively deteriorating condition with a 
mortality rate of 2-3 times higher than the general population, with two-thirds of those 
excess deaths attributed to suicide (Auquier, Lancon, Rouillon, & Lader, 2007; Brown, 
1997).  
 Characterizations of the contemporary symptomology of the disorder began with 
Emil Kraeplin (1896) who called the syndrome Dementia Praecox emphasizing the early 
adulthood onset of symptoms and the deterioration of thought processes. The term 
schizophrenia was coined by Eugene Bleuler (1911) from the Greek words schizein (which 
means split) and phren (which means mind), referring to the separation between mind and 
emotion.  
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Symptomology of Schizophrenia 
 According to the Diagnostic and Statistical Manual of Mental Disorders IV text 
revision (DSMIV-TR) the symptomology of schizophrenia is characterized by two broad 
symptom categories: positive (added or disproportionate occurrence with the disease) and 
negative (normal occurrence is deteriorated) symptoms. However, there is increasing 
research that supports adding cognitive dysfunction as another core set of symptoms 
(Goldman-Rakic, 1994; Joyce & Roiser, 2007; Keefe & Fenton, 2007). Positive symptoms 
include: delusions (flawed beliefs involving distortion of perception or experiences), 
hallucinations (including auditory, gustatory, visual, olfactory and tactile), disorganized 
speech (formal thought disorder), and grossly disorganized or catatonic behavior (self-
monitoring of behavior). Furthermore these positive symptoms fall under two distinct 
dimensions, psychotic dimension and the disorganized dimension that may have separate 
neural basis. Hallucinations (most commonly auditory) and delusions fall under the 
psychotic dimension while disorganized speech and behavior fall under the disorganized 
dimension.  
 Delusions are non-logical beliefs held by the patient that cannot be changed even 
after the patient has been shown logical proof that their beliefs are not true. These 
delusions are frequently bizarre and can include beliefs that persons in movies or television 
are sending messages to them specifically. They can also believe that they are a famous 
historical figure or some special messiah (delusions of grandeur). Those with paranoid 
delusions believe that others are out to get them or persecute them in some way. 
Hallucinations are sensory experiences felt by the patient that are not able to be 
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experienced by anyone else. Hearing voices is widespread in the patient population, and 
these voices are most frequently negative in content and may comment on the person’s 
behavior, converse between themselves (usually about the patient), or warn of impending 
doom or danger. These hallucinations may also include the other senses like seeing 
nonexistent persons or objects, feeling phantom touches, or even smelling odors not 
present. Another positive symptom is unusual thought processes. One striking form is 
disorganized thinking, the person would have great difficulty organizing their thoughts or 
connecting them in a logical way. Their speech may be jumbled and hard to understand. 
Another form is "thought blocking," in which the person stops abruptly in the middle of a 
thought. The patient would explain this by saying the thought had been snatched out of 
their head. Also the patient may make up words or “neologisms” that only make sense to 
them. Finally, positive symptoms also include disorganized or catatonic behavior. Patients 
are often clumsy or uncoordinated in their movements. They may also have involuntary 
movements like facial grimaces or muscle tics. They may also have difficulty initiating 
behaviors and in some cases cease movement altogether (catatonia). Catatonia is now 
extremely rare and occurred mostly before effective neuroleptics were available (Weder, 
Muralee, Penland, & Tampi, 2008). 
 Negative symptoms include flattened affect (a reduction in range and intensity of 
emotion), alogia (a reduction in the fluency and productivity of language and thought), 
anhedonia (an inability to feel pleasure), and avolition (lack of initiation of goal directed 
behavior). Flattened affect is a difficulty in expressing emotion in the correct facial and 
vocal context as well as an inability to control the intensity of that expression. A patient 
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may say they are very sad about something but laugh and smile while saying this. Patients 
may also have difficulty in expressing in words any idea or thought, and can resist verbal 
interaction even if initiated by others (alogia). Another negative symptom is the lack of 
pleasure or enjoyment that comes from everyday experiences (anhedonia). 
 Most patients with schizophrenia have some form of cognitive deficit (Meltzer, 
Thompson, Lee, & Ranjan, 1996). Cognitive symptoms of schizophrenia include severe 
impairments (2-3 standard deviations [SD] below mean) in verbal memory, executive 
functioning, vigilance, motor speed and verbal fluency. There are also moderate 
impairments (1-2 SD below the mean) in distractibility, delayed recall, visuo-motor skills, 
immediate memory span, and working memory. In addition there are mild impairments 
(0.5-1 SD below the mean) in perceptual skills, delayed recognition memory, confrontation 
naming, and verbal and full scale IQ (Keefe, 2007). These cognitive deficits are being 
recognized as an essential indicator of functional outcomes in those diagnosed with 
schizophrenia (McEvoy, 2008). The National Institute of Mental Health (NIMH) has 
recognized the importance of cognitive deficits in Schizophrenia and has established 
MATRICS™ (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) to better understand and approach diagnosis and treatment of cognitive 
deficits in Schizophrenia (Green et al., 2004).  
Pharmacology and Pharmacotherapy of Schizophrenia 
 Pharmacological treatment using first generation or typical antipsychotics started 
with the development of chlorpromazine in the early 1950’s. This revolutionized patient 
treatment as most patients before the availability of drug intervention were 
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institutionalized. The development of the phenothiazine chlorpromazine revolutionized the 
mental health industry and helped initiate the field of behavioral pharmacology 
(Thompson, 1977). Further development of typical antipsychotics, such as haloperidol (a 
butyropherone) relied heavily on Dopamine (DA) antagonist action, specifically 
postsynaptic blocking of the D2 receptor subtype. This was further evidenced in their 
ability to cause extrapyramidal motor side-effects (EPS) (Carlsson & Lindqvist, 1963). At 
first these side-effects were seen as proof that the drugs were working. However, these 
motor tremors and slurred speech were eventually identified as undesirable side-effects. 
These first antipsychotic drugs functioned based on their ability to reduce dopaminergic 
activity in the mesolimbic and mesostriatal pathways. The pharmacological evidence of 
clinical efficacy was the basis for the Dopamine Hypothesis that was supported by 
numerous methods of study, from imaging to postmortem (Honey et al., 1999; Seeman, 
1987). However, the pathology was more complex than simply a hyper-dopaminergic 
system. Currently this hypothesis has been refined to include more complex relationships 
between multiple DA pathways, and not just hyperactivity of DA. The revised hypothesis 
of DA in schizophrenia postulates that this disorder is associated with excess DA activity 
in the subcortical mesolimbic projections (associated with positive symptoms) together 
with hypoactivity in mesocortical DA projections to the prefrontal cortex (associated with 
negative symptoms including cognitive deficits) (Toda & Abi-Dargham, 2007).  
 Pharmacotherapy of schizophrenia remained tied to this theory until the 
development of clozapine, the first atypical APD. Clozapine was first synthesized by 
Wander Laboratories in 1958, but was not used as an antipsychotic until 1971. Shortly 
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after its introduction in Europe (1974) several patients died as a result of agranulocytosis 
and it was pulled from the market and other clinical trials suspended. Clozapine was not 
reintroduced until two trials in 1988 showed efficacy in treatment of refractory patients. 
The FDA approved clozapine for treatment of treatment resistant schizophrenia in 1990 
(Hippius, 1999). Atypical antipsychotic drugs such as clozapine display a diverse 
mechanism of action at numerous receptors with less activity at DA receptors, as well as a 
reduced liability for extrapyramidal side effects at clinically prescribed doses compared to 
typical antipsychotics.  Some have argued that one method of classification between 
typical and atypical antipsychotic drugs should be based on serotonergic activity (Meltzer, 
Matsubara, & Lee, 1989a, 1989b). However, some atypical antipsychotic drugs do not 
have serotonergic activity similar to clozapine, like aripiprazole that displays some partial 
agonism at D2 and 5-HT1A receptors with potent antagonism at 5-HT2A receptors (Hirose et 
al., 2004; Taylor, 2003). Further characterization is needed to fully understand the 
mechanisms of action required for antipsychotic action.  
Glutamate Hypothesis of Schizophrenia 
 The dominant hypothesis in schizophrenia as previously mentioned is the 
Dopamine Hypothesis, and current pharmacotherapies have reflected this emphasis. 
Recently however, more research (Coyle, 2006; Goff & Coyle, 2001; Ibrahim et al., 2000; 
Meador-Woodruff & Healy, 2000; G. Tsai & Coyle, 2002) has focused on the role of 
glutamate (GLU) in schizophrenia and a Glutamate Hypothesis is now gaining research 
attention. Some reasoning GLU has been explored is due to the ability of NMDA 
antagonists such as ketamine and phencyclidine to induce psychotic-like positive, negative, 
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and cognitive symptoms in non-schizophrenic humans (Itil, Keskiner, Kiremitci, & 
Holden, 1967; Krystal et al., 1994; Luby, Cohen, Rosenbaum, Gottlieb, & Kelley, 1959). 
An additional reason is that GLU is the most common excitatory cortical neurotransmitter. 
Due to the specific dysfunctions of the disorder, the GLU pathways are most likely 
involved in the pathology of the disease (Carlsson, Hansson, Waters, & Carlsson, 1997). 
Multiple subtypes of glutamate receptors are involved in the pathology of schizophrenia. 
Many deficits, according to this hypothesis, are explained by the disproportionate 
sensitivity of a specific subpopulation of NMDA receptors, located on cortico-limbic 
GABAergic interneurons, to NMDA antagonists  (Coyle, Tsai, & Goff, 2003; G. Tsai & 
Coyle, 2002), which is supported by neurophysiologic studies and the cortical disinhibition 
seen upon the administration of ketamine at subanesthetic doses (Krystal et al., 1994). This 
cortical disinhibition is also supported by imaging studies (Weinberger & Gallhofer, 1997). 
Additional reasoning behind this hypothesis is the interaction of DA and GLU neurons in 
diverse brain areas. Some of those interactions are inhibitory DA action on GLU release, 
GLU stimulation of neurons that inhibit DA release, and GLU excitatory action on neurons 
that DA inhibits. Antipsychotics that are DA antagonists indirectly increase GLU levels 
(Collier & Li, 2003; Lang, Puls, Muller, Strutz-Seebohm, & Gallinat, 2007; Mehler-Wex 
& Renner, 2008; Mehler-Wex, Riederer, & Gerlach, 2006; Moghaddam, Adams, Verma, 
& Daly, 1997; Stone, Morrison, & Pilowsky, 2007). 
Drug Discrimination 
Drugs can function in a variety of ways to control behavior, discriminative, reinforcing, 
punishing, and unconditioned stimuli (Schuster & Balster, 1977). Drugs have unique 
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interoceptive effects that can be used as discriminative stimuli in an operant paradigm to 
distinguish different aspects of a drug’s pharmacological profile (Overton, 1966). Overton 
(1966) defined operant drug discrimination as when the specific feeling that occurs in a lab 
animal’s internal environment is used to cue them to make a certain operant response. In 
drug discrimination with rodents the interoceptive effects involved in a certain stimulus are 
often associated with an action like pushing a lever or making a directional choice in a 
maze. In the operant version of drug discrimination a drug at a specific dose is associated 
with one operant lever (training drug) and vehicle (an inactive substance) is associated 
with another lever. This allows the researcher to interpret the responses on those levers 
during testing as being like the training drug or not being like the training drug (Harris & 
Balster, 1971). Determining dose effects, generalization curves, or stimulus gradients are 
common characterizations that this paradigm is used for. Clozapine drug discrimination 
has been established in many animal species including rats (Goas & Boston, 1978; Prus, 
Baker, & Meltzer, 2004), monkeys (Carey & Bergman, 1997a), pigeons (Hoenicke, 
Vanecek, & Woods, 1992) and most recently mice (Philibin, Prus, Pehrson, & Porter, 
2005).  
NMDA drug discrimination has been conducted in rats (Amrick & Bennett, 1987; 
Arnt, Sanchez, Lenz, Madsen, & Krogsgaard-Larsen, 1995; Balster, 1989; Willetts & 
Balster, 1989) and in pigeons and non-human primates (Baron, Butelman, & Woods, 
1993). Drug discrimination has been used with ligands that act selectively on specific 
receptors to further classify the pharmacological properties of a drug’s stimulus effects 
such as onset and duration of activity, structure-activity relations, mechanism of action, 
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tolerance and withdrawal, activity of metabolites, identification and development of 
potential antagonists and similarity of effect to other agents. Drugs that belong to the same 
class substitute for each other in the drug discrimination paradigm, for instance 
amphetamine and cathinone cross-generalize to each other’s stimulus cues (Stolerman & 
D'Mello, 1981). This implies that compounds that share discriminative stimulus properties 
with the training drug could have similar pharmacological actions (Brady & Balster, 1981). 
This has led to the use of drug discrimination in the study of drugs of abuse in an effort to 
look for the action of addiction and for developing new drug treatments (Holtzman, 1990). 
Drug discrimination is also used as a preclinical assay to study existing drug treatments 
and to aid in the development of new therapeutic drugs for many other psychological 
diseases including schizophrenia. Previous studies have used clozapine drug discrimination 
to compare the discriminative effects of clozapine to other atypical antipsychotic drugs 
(Goas & Boston, 1978; Overton, 1982; Philibin et al., 2005; Porter, Varvel, Vann, Philibin, 
& Wise, 2000; Prus et al., 2004; Prus, Philibin, Pehrson, & Porter, 2005, 2006). In 
understanding the effects of clozapine in relation to other atypical antipsychotic drugs we 
may gain key insights into the mechanisms of action required for antipsychotic action as 
well as possibly identify receptor subtype targets for future drug development (Ortmann et 
al., 1986).  
Discriminative Stimulus of Clozapine 
Clozapine is often referred to as the gold standard of atypical antipsychotic drugs due 
to its superior clinical efficacy. Research suggests that the cue is complex and may require 
multiple coordinated receptor actions. The precise receptor subtypes necessary to the cue 
 9
   
have yet to be determined, which may be due in part to its multi-receptor binding profile 
(i.e., high binding affinity for serotonergic, dopaminergic, adrenergic, muscarinic and 
histaminergic receptors). 
  One of the first drug discrimination studies to use clozapine as a training drug in a 
two lever operant paradigm was by Goas and Boston (1978). They trained two different 
groups of rats, one to discriminate 6.0 mg/kg clozapine (oral) from saline. Several classes 
of compounds chlorpromazine, haloperidol, chlordiazepoxide and atropine failed to 
substitute for clozapine. A second group of rats was trained to discriminate 8.0 mg/kg 
clozapine from 4.25 mg/kg chlorpromazine (both oral), and haloperidol substituted for 
chlorpromazine (Goas & Boston, 1978). Using a t-maze paradigm instead of two-lever 
operant, Overton (1982) trained rats to discriminate 20 mg/kg clozapine from 2.5 mg/kg 
haloperidol (both intraperitoneal). However, in using a t-maze only choice can be recorded 
with no gradation of dose or partial substitution (Overton, 1982).   
 In pigeons trained to discriminate 1.0 mg/kg clozapine (intramuscular), antagonists 
of 5-HT2A and 5-HT2C receptors (cyproheptadine, metergoline, fluperlapine, mianserin and 
pizotifen) substituted for the CLZ cue in all animals (Hoenicke et al., 1992). However, 
these results may be species specific as they have not been repeated in rats. Previous 
research from our lab in rats trained to discriminate clozapine vs. vehicle (J. L. Wiley & 
Porter, 1992) and clozapine vs. haloperidol (Wiley & Porter, 1993), all delivered 
intraperitoneally, showed ritanserin, a 5-HT2A/B/C antagonist failed to substitute for 
clozapine. However, in C57BL/6 mice trained to discriminate 2.5 mg/kg (subcutaneous) 
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clozapine from vehicle, serotonin (5-HT)2A/2B/2C antagonist ritanserin fully substituted for 
CLZ with an ED50 = 2.08 mg/kg (Philibin et al., 2005).  
 Dopamine blockade alone by specific ligands does not engender clozapine 
responding in rats as evidenced by the failure of the dopamine D1 receptor antagonist SCH 
23390 to substitute for clozapine in rats (Franklin & Tang, 1994; Goudie, Smith, Taylor, 
Taylor, & Tricklebank, 1998; Porter, Villanueva, & Rosecrans, 1999) and in pigeons 
(Hoenicke et al., 1992). Clozapine responding is also not engendered by D2 antagonists 
(Browne & Koe, 1982; Franklin & Tang, 1994; Goas & Boston, 1978; Goudie et al., 1998; 
Porter et al., 1999; Tang, Franklin, Himes, Smith, & Tenbrink, 1997; Villanueva, Arezo, & 
Rosecrans, 1992; J. Wiley & Porter, 1993) or in squirrel monkeys (Carey & Bergman, 
1997b) nor by D4 and D3 antagonists in rats (Goudie et al., 2001; Goudie et al., 1998). In 
C57BL/6 mice trained to discriminate 2.5 mg/kg clozapine (subcutaneous) from vehicle 
the DA2 antagonist and typical antipsychotic haloperidol did not substitute for clozapine, 
producing a maximum of 51.6% DLR at the 0.2 mg/kg dose (subcutaneous) of haloperidol 
(Philibin et al., 2005). 
 Many atypical antipsychotics generalize to the clozapine cue as is evidenced by 
previous research from our lab that shows olanzapine, quetiapine and ziprasidone fully 
substitute in rats trained to discriminate 5.0 mg/kg clozapine vs. vehicle delivered 
intraperitoneal (Prus et al., 2005). Typical antipsychotics chlorpromazine, fluphenazine 
and perphenazine did not substitute, while the atypical antipsychotics risperidone and 
sertindole produced partial substitution for clozapine with 60-79% clozapine-lever 
responding (Prus et al., 2005). However, it should be noted that in rats trained to 
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discriminate 1.25 mg/kg clozapine vs. vehicle (intraperitoneal) sertindole and risperidone 
fully substituted for the clozapine cue (Porter et al., 2000). In C57BL/6 mice trained to 
discriminate 2.5 mg/kg (subcutaneous) from vehicle olanzapine produced full substitution 
for CLZ at the 1.0 mg/kg (87.3% DLR) and 2.0 mg/kg (86.7% DLR) doses. Risperidone 
also fully substituted for CLZ at two doses with 86.1% DLR at 0.25 mg/kg and 95.0% 
DLR at 0.50 mg/kg. Ziprasidone produced full substitution for CLZ at the 1.0 mg/kg 
(83.3% DLR) and 2.0 mg/kg (93.6% DLR) doses (Philibin et al., 2005). 
 Pyrilamine, an H1 histaminergic antagonist, fails to substitute for clozapine in rats, 
intraperitoneal (Goudie et al. 1998) or pigeons, intramuscular (Hoenicke et al. 1992).  But 
when H1 antagonists that also have antagonist properties at multiple 5-HT and muscarinic 
sites (promethazine and cyproheptadine) are tested they fully substitute for clozapine in 
rats, intraperitoneal (Kelley & Porter, 1997). Adrenergic antagonists fail to substitute 
clozapine in rats, intraperitoneal (Goudie et al., 1998; Kelley & Porter, 1997; Nielsen, 
1988) pigeons, intramuscular (Hoenicke et al. 1992), but not in C57BL/6 mice, 
subcutaneous (Porter, Walentiny, Philibin, Vunck, & Crabbe, 2008).  
Discriminative Stimulus of NMDA  
 The discriminative properties of NMDA have been explored in rats (Amrick & 
Bennett, 1987; Willetts & Balster, 1989), and in pigeons and non-human primates (Baron 
et al., 1993) but not in mice. Many NMDA antagonists have been characterized via drug 
discrimination as well (Balster, 1989; Holter, Danysz, & Spanagel, 2000; Hundt, Danysz, 
Holter, & Spanagel, 1998; Koek, 1999; Koek, Woods, & Colpaert, 1990; Medvedev, 
Dravolina, & Bespalov, 1998; Willetts, Bobelis, & Balster, 1989). A study by Amrick and 
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Bennett (1987) found that rats learned to discriminate 30 mg/kg NMDA from saline in 
approximately 45 sessions, with a 60% successful training rate. The generalization curve 
was dose dependant with an ED50 value = 13.6 mg/kg (intraperitoneal delivery). The 
specific NMDA receptor antagonist, 3-((±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic 
acid (CPP), intraperitoneal, blocked NMDA-induced discriminative stimuli confirming 
that the NMDA cue was mediated by activation of NMDA receptors (Amrick & Bennett, 
1987). In a second comparison study it was found that ketamine and dexoxadrol, both 
NMDA antagonists, blocked the stimulus properties of NMDA without behavioral 
interference (Bennett, Bernard, & Amrick, 1988). 
 Grech, Lunn, & Balster (1995) trained rats to discriminate 30 mg/kg NMDA, via 
intraperitoneal delivery, from saline and investigated the discriminative stimulus properties 
of a number of excitatory amino acids in this assay. LY 285265 produced full substitution 
at a dose of 0.3 mg/kg (> 95% NMDA-lever responding) in all subjects, with an ED50 
value of 0.17 mg/kg. Complete rate suppression occurred at the next highest dose tested 
1.0 mg/kg (Grech, Lunn, & Balster, 1995). Generalization testing with L-glutamate (30-
560 mg/kg) was also completed and resulted in partial substitution for NMDA, producing a 
maximum of 59% NMDA-lever responding. Partial substitution was also observed with 
monosodium glutamate (100-3000 mg/kg), which produced a maximum of 49% NMDA-
lever responding, with partial rate suppression at the 3000 mg/kg dose. Higher dose testing 
was not completed in all animals after two deaths at the 6000 mg/kg dose. L-cysteine 
failed to substitute for NMDA with a maximum of 33% NMDA-lever responding. L-
cysteine at l000 mg/kg produced rate suppressant effects. L-Homocysteic acid (100-1500 
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mg/kg) achieved partial substitution for NMDA, producing maximum values of 61-67% 
NMDA-lever responding at doses of 1000 and 560 mg/kg, respectively. Rate suppression 
occurred at the 1500 mg/kg dose. Kainic acid (0.1-3 mg/kg) was tested in five subjects, 
and produced <40% NMDA-lever responding at a single dose of 1 mg/kg, three subjects 
were tested at a 5.6 mg/kg dose which generated lethality so no further testing was 
completed (Grech et al., 1995). Many of the amino acid compounds did not produce 
behavioral effects even up to lethal doses. L-Aspartate (30-300 mg/kg) also failed to 
substitute for NMDA, producing <17% NMDA-lever responding. No rate suppressant 
effects were observed.  
 The stimulus effects of competitive vs. noncompetitive antagonists of NMDA 
differed in a study in which rats were trained to discriminate 30 mg/kg NMDA from saline, 
with an ED50 of 17.1 mg/kg (Willetts & Balster, 1989).  PCP and (+)-NANM 
(noncompetitive antagonists) failed to antagonize the cue even at doses that affected 
response rates. MK-801, pentobarbital, and diazepam mildly antagonized NMDA 
responding but did not fully block NMDA’s discriminative cue even at rate disruptive 
doses (Willetts & Balster, 1989). The competitive antagonists NPP and NPC12626 
completely antagonized the NMDA cue and when NPP and NPC 12626 (as well as CGS 
19755) were tested alone they surprisingly produced NMDA like responding at close to 
generalization levels though only in four of the eight animals (Willetts & Balster, 1989). In 
a later study (Balster, Grech, & Bobelis, 1992) ethanol failed to antagonize NMDA 
stimulus effects though it had been shown to produce similar stimulus effects as other 
NMDA antagonists (Balster et al., 1992).   
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 In rats trained to discriminate 20 mg/kg pentobarbital, intraperitoneal, stimulus 
properties of NMDA antagonists were evaluated. The competitive N-methyl-D-aspartate 
(NMDA) antagonist 3−[(±)–2-carboxypiperazin-4-yl] propyl-1-phosphonic acid (CPP) 
substituted for pentobarbital.  The uncompetitive NMDA antagonist, dizocilpine (MK-801) 
partially substituted for pentobarbital (Willetts, Tokarz, & Balster, 1991). Additional 
characterizations of the affects of competitive and uncompetitive antagonists on the 
stimulus effects of NMDA have been studied in rats trained to discriminate 40 mg/kg 
NMDA, intraperitoneal, from saline (Koek et al., 1990). The findings were similar to those 
of Amrick & Bennett (1987) as CPP and CGS 19755 blocked the NMDA cue. Similar to 
findings in the Willets and Balster (1989) study CGS 19755 produced NMDA responding 
when tested alone. Additionally ketamine (in contrast to previous studies) did not fully 
block the NMDA cue, while PCP and MK-801 partially blocked the cue as in previous 
studies (Koek et al., 1990).  
 Swiss-Webster mice were trained to discriminate the uncompetitive NMDA 
receptor antagonist, dizocilpine 0.17 mg/kg, subcutaneous, from saline in a T-maze. 
Several uncompetitive antagonists substituted for dizocilpine: TCP, SKF 10,047, 
dextrorphan, and PCP. While, competitive NMDA antagonists CGS 19755, NPC 17742, 
(+/-)CPP and LY 233536 also substituted for dizocilpine suggesting similarities in the 
stimulus properties of competitive and noncompetitive NMDA antagonists (Geter-
Douglass & Witkin, 1997). 
 In a study by Baron and Woods (1989) Pigeons were trained to discriminate 0.64 
mg/kg (intramuscular) of phencyclidine (an uncompetitive NMDA antagonist) vs. vehicle. 
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Other uncompetitive antagonists MK-801, etoxadrol, and dexoxadrol generalized to the 
phencyclidine cue while competitive antagonists AP-5 and AP-7 did not generalize (Baron 
& Woods, 1989). 
 However, not all NMDA drug discrimination studies have found clear 
pharmacological specificity. Baron et al. (1993) trained both pigeons (intramuscular) and 
monkeys (subcutaneous) to discriminate NMDA (5.6 mg/kg NMDA for both) from saline. 
Similarly to previous studies PCP failed to fully antagonize NMDA, but unlike previous 
studies CGS 19755 did not engender NMDA responding. However, kainite, AMPA, 
morphine, pentobarbital, and d-amphetamine generalized to the NMDA cue in at least half 
of the pigeons. As these drugs are from several different drug classes, this suggests that 
perhaps this particular study fell short of establishing pharmacological specificity in the 
drug discrimination (Baron et al., 1993).  
 A study involving the specificity of NMDA drug discrimination (Grech, Willetts, & 
Balster, 1993) in which rats were trained to discriminate 30 mg/kg NDMA, intraperitoneal,  
from saline sought to clarify drug class differences in this assay. Various pharmacological 
agents from many drug classes were tested. Caffeine and amphetamine, both stimulants, 
did not substitute for NMDA. Additionally, morphine (an opiate), pentylenetetrazol (an 
epileptegenic) and picrotoxin (a GABA antagonist) did not substitute for NMDA. The 
cholinergic drugs nicotine (nicotinic agonist), physostigmine (a reversible cholinesterase 
inhibitor), arecoline (muscarinic agonist) and mecamylamine (nicotinic antagonist), 
produced only low partial NMDA responding and only at doses that had rate suppressing 
effects (Grech et al., 1993).  
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 Comparisons of the AMPA agonist ATPA to NMDA in a drug discrimination study 
with two groups of rats trained to discriminate 40mg/kg NMDA or 5 mg/kg ATPA, both 
intraperitoneal, from saline found that the two drugs did not generalize to each other. The 
NMDA agonists (RS)-tetrazol-5-yl-glycine and AMAA both generalized to the NMDA 
cue in rats trained to discriminate 40 mg/kg NMDA, intraperitoneal (Arnt et al., 1995) 
 Compounds that bind to the glycine modulatory site on the NMDA receptor also 
have been evaluated via drug discrimination. The two novel quinoxalinedone 
glutamatergic antagonists ACEA-1011 and ACEA-1021 that have in vitro selectivity for 
the glycine modulatory site fail to block the NMDA stimulus cue in rats trained to 
discriminate 30 mg/kg NMDA, intraperitoneal, from saline (Balster et al., 1995). Also, in a 
study investigating lead exposure effects on stimulus properties of NMDA rats were 
trained to discriminate 30 mg/kg NMDA, intraperitoneal, after exposure to 0, 50 or 150 
ppm lead acetate in drinking water post-weaning (Cory-Slechta, Pokora, & Johnson, 1996). 
The D2 antagonist spiperone achieved full substitution and the D1 antagonist SCH23390 
produced partial substitution (Cory-Slechta et al., 1996).  
 In a study investigating α1-adrenoreceptors one group of rats were trained to 
discriminate 30 mg/kg NMDA, intraperitoneal, from saline. The atypical antipsychotics 
clozapine and sertindole both engender partial substitution. The α1-adrenoreceptor 
antagonists prazosin and WB 4101 fully substitute for NMDA (Arnt, 1997).
  
Rationale 
Although the Dopamine Hypothesis remains dominant in the explanations of 
schizophrenia; it does not fully explain the complexities of the disorder. In addition to 
abnormalities in brain DA systems there are abnormalities in glutamatergic systems, which 
have led to the Glutamate Hypothesis. The interplay between dopamine and glutamate 
systems suggested by recent research implies that a combination of the two hypotheses 
may be a more accurate portrayal of the disorder. Therefore it is important to understand 
the interactions between these two systems. One approach to understanding these 
interactions on a behavioral level is drug discrimination.  
 Previous research in this lab (Kelley & Porter, 1997) found that NMDA failed to 
substitute for clozapine in rats. However, when a T-maze drug discrimination task was 
used, NMDA substituted for clozapine (Schmidt & Volz, 1992). Arnt (1997) in research 
with α1 antagonists showed partial substitution of clozapine and full substitution of 
prazosin, an α1-adrenoresptor antagonist, in 30 mg/kg NMDA-trained rats, even though 
neither clozapine or prazosin has been shown to have an affinity for NMDA receptors. In 
clozapine (1.25 and 5.0 mg/kg) trained rats prazosin does not substitute for the clozapine 
cue (Prus et al., 2006). However, recently published data from this lab (Porter et al., 2008) 
showed that prazosin produced full substitution in C57BL/6 mice trained to discriminate 
2.5 mg/kg CLZ. This suggests that α1-adrenoresptor antagonism may play a role in the 
stimulus cue of NMDA in C57BL/6 mice. Although some NMDA antagonists have been 
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trained as discriminative stimuli in mice, NMDA has never been trained as the 
discriminative stimulus in mice. I propose to train two groups of C57BL/6 mice, one to 
discriminate NMDA from vehicle and another to discriminate CLZ from vehicle. 
Generalization curves will be generated for both training drugs in both groups to ascertain 
if there is any cross-generalization between CLZ and NMDA. Further comparisons 
between the two compounds using selective ligands will elucidate the similarities and 







Twenty four adult male C57BL/6NHsd wild-type mice (Harlan, Indianapolis, IN) 
weighing 20-25g were utilized as subjects. The mice were acclimatized to normal lab 
handling and free-feeding weights were obtained for fourteen days. Then the mice were 
removed from free food and maintained at 85% of their free feeding body weights via 
restricted food (water was available ad libitum in the home cages). The food provided in 
home cages was from Harlan Teklad Lab Diets (Teklad LM-485, Madison, WI) and 
bedding was sanichips (Teklad, Madison, WI). The mice were housed individually in a 
temperature-controlled vivarium at 22-24 degrees Celsius with a 12 hour light/dark cycle 
(lights on at 0600h and off at 1800h) and transported daily (0830h) to the laboratory where 
they remained until procedures were complete for the day (1100h). Research was 
performed in agreement with the Guide for the Care and Use of Laboratory Animals 
(National Research Council, 2003) and all procedures were approved by the Institutional 
Animal Care and Use Committee at Virginia Commonwealth University (IACUC Protocol 
AM10284). The initial number of twenty four mice was chosen to ensure that after initial 
acquisition at least twenty mice had acquired the task. As the design was within-subjects, 
each mouse served as its own control. A power analysis (power = 0.8, alpha = 0.05) 
indicated that 8-10 mice per group were sufficient to detect significant treatment effects. 
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Apparatus 
The experiments were conducted in six standard sound attenuating operant chambers 
(Model BNV-307A, Med Associates, St. Albans, VT). Experimental sessions and data 
collection were controlled by Med-PC for Windows software (version 1.17; Med Associates). 
The internal operant chamber (15 cm L X 11.5 cm D X 17.5 cm H) had a stainless steel grid 
floor with Plexiglas walls and roof and a stainless steel intelligence panel. The operant test 
chambers contained two retractable levers (0.8 cm when extended and located 2.5cm above the 
grid floor) that were placed equidistantly from a recessed well (centered on the intelligence 
panel) where a liquid dipper could be accessed. The liquid dipper delivered 0.02 mL of 
sweetened reconstituted milk (25% powdered non-fat dry milk, 25% sugar, 50% tap water).  
Drugs 
Clozapine (gift from Novartis, Hanover, NJ) and NMDA (gift from Lundbeck DK, 
Copenhagen–Valby, Denmark) and prazosin (purchased from Sigma Aldrich; St. Louis, MO) 
were dissolved in 50 mL deionized water with two drops of 85% lactic acid. The vehicle 
(VEH) solution consisted of 50 mL deionized water plus two drops of 85% lactic acid. 
Injections were administered subcutaneously (SC) 30 minutes prior to test sessions at a volume 
of 10 ml/kg body weight.  
Procedure 
Single Lever Training. Subjects were trained to press the VEH lever on a Fixed Ratio 1 
(FR 1; every 1 lever press resulted in the delivery of a reinforcer) food reinforcement schedule 
for the sweetened milk reinforcer in 15 minute operant sessions. To facilitate bar press training 
one drop of milk was placed directly on the lever at the beginning of the session. Once bar 
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pressing was established, the FR schedule was gradually increased (1 FR per day) to FR 10. 
Subjects were randomly assigned to either the CLZ group (N = 12) or to the NMDA group (N 
= 12) and the operant chamber assignments for the two groups were counterbalanced. The 
mice were trained with single-lever errorless training with only a single lever extended into the 
test chamber. The mice were first trained with VEH injections (only the VEH-appropriate 
lever was present). After response rates stabilized on the VEH lever, the mice received training 
with drug injections (either 2.5 mg/kg CLZ or 30 mg/kg NMDA) and were trained on the 
opposite (i.e. DRUG) lever. The DRUG-lever location was counterbalanced between groups to 
avoid possible confounding by olfactory cues (Extance & Goudie, 1981). Tolerance to rate 
suppression effects of the training drugs was seen after approximately one week (mice were 
allowed to recover to VEH levels of responding). 
 Drug Discrimination Training. Following single-lever training, the mice then 
received their training drug (2.5mg/kg CLZ or 30mg/kg NMDA) or VEH on a double-
alternation schedule (DDVVDDVV) with both levers present in the test chambers. Only 
responses on the correct lever were reinforced and a response on the non-appropriate lever 
during a string of responses reset the FR counter on the correct lever; for example, if the 
animal received a DRUG injection they were rewarded only for pressing the lever that they 
had previously been trained to associate with DRUG. In order to pass discrimination 
training, the mice had to meet three criteria in 5 of 6 consecutive training days: 1) 
completion of the first FR (FFR) on the condition-appropriate lever; 2) a minimum 
response rate of 10 responses per minute (RPM) during each session; and 3) 80% or 
greater responding on the condition-appropriate lever. 
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 Generalization and Substitution Testing. Once drug discrimination training was 
successfully completed, subjects moved on to generalization testing with the training 
drugs. During Test Sessions, both levers were reinforced, but as before, switching levers 
during a string of responses reset the FR counter. Test Sessions was generally conducted 
on Wednesdays and Saturdays but could occur on any day that the subject met testing 
criteria. The testing criteria included a minimum of two training days (had to include both 
a DRUG and a VEH training session) between tests and each animal was required to pass 
two consecutive days of training (one of each condition) before testing. The double 
alternation training schedule was maintained between Test Sessions. Both training DRUG 
and VEH control tests were established before each drug dose response curve in order to 
determine that the training drugs were maintaining good stimulus control. All housing, 
training and testing conditions were identical to those used by Philibin et al. (2005). 
 After generalization dose response curves were obtained for the training drugs, 
cross-generalization testing for the two training drugs was conducted to determine if they 
would substitute for the other training drug. Since it was found that the two training drugs 
did not cross-generalize to each other, combination testing was conducted. A dose for 
NMDA and for CLZ that engendered less than 35% DLR in the generalization curves was 
chosen (10 mg/kg for NMDA and 0.625 mg/kg for CLZ). Then the dose response curves 
for each drug were re-determined in combination with either the low dose of NMDA or 
CLZ.  A single selective ligand was tested, the α1-adrenoreceptor antagonist, prazosin. 
Further testing with other compounds was not completed.  
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  Data Analysis. For all sessions, the Med-PC software was programmed to calculate 
the percent drug-lever responding (%DLR) by counting the total lever responses on the 
condition appropriate lever, dividing that by the total number of responses on both levers, 
and then multiplying that by 100. Responses per minute (RPM) were calculated by taking 
the total number responses on both levers and dividing by fifteen. A subject’s %DLR was 
excluded from data analysis if they did not complete an FFR (i.e. received a reinforcer) or 
if their RPM < 2. However, all response rates were included in the calculation of the RPM 
data, even if it was 0 (i.e. no responses during the session). Full substitution to the drug cue 
was defined as > 80% DLR. Partial substitution to the drug cue was defined as > 60% and 
< 80% DLR. No substitution to the drug cue was defined as < 60% DLR. Effective dose50 
(ED50) values were calculated for the linear portion of the dose response curve for any drug 
that produced full substitution (Goldstein, 1964).  Values for ED50 were calculated using 
least squares linear regression analysis, followed by calculation of confidence limits as by 
Bliss in Statistics in Biology (1967). For each drug tested a repeated-measures analysis of 
variance (ANOVA) compared RPM at each dose to the vehicle control point for that drug 
(GB-STAT software, Version 10; Dynamic Microsystems, Inc., Silver Spring, MD). 
Significant ANOVAs were followed by Newmen-Keuls post-hoc tests (p < 0.05). 
 





 Ten of the original twelve mice were successfully trained at 2.5 mg/kg CLZ 
(Fig.1); two mice were removed from the study due to an inability to gain tolerance to the 
rate-suppressing effects of the drug (40 days total without showing tolerance). The average 
number of sessions until CLZ animals met criteria was 25.2 (SEM ±10.9) with a range of 
10-39 sessions which was consistent with  previous results from our lab (Philibin et al., 
2005).  NMDA was successfully and reliably trained at a dose of 30mg/kg in all twelve 
C57BL/6 mice (Fig. 2). The average number of sessions to completion of criteria was 27.3 
with a range of 14-56 (SEM ± 11.4) sessions. The number of sessions to reach criteria did 
not differ significantly between the two drugs (t20= 0.44, p= 0.67).  
Generalization  
 For clozapine’s dose effect curve, the training dose of 2.5 mg/kg (96.68%DLR) and 
the 5.0 mg/kg (100%DLR) dose produced full generalization (Fig. 3). The highest dose 5 
mg/kg produced profound rate suppression as only two of the ten animals responded (F
7, 79 
= 16.14, p < 0.0001). Clozapine in this curve had an ED50 = 0.92 mg/kg (95% C.I. = 0.66-
1.29 mg/kg).  
The dose effect curve for NMDA was completed by eleven animals. One animal 
was removed after consistently failing to complete control points over a period of four 
weeks. The training dose of 30 mg/kg as well as the 56 mg/kg dose engendered full 
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generalization as illustrated in Figure 4. Drug lever responding for these two doses was 
96.9% and 97.0% respectively. Significant rate suppression occurred at the 56 mg/kg dose 
(F
5, 65 
= 12.15, p < 0.0001). The ED50 was calculated at 10.8 mg/kg (95%C.I= 7.69-15.16 
mg/kg) for the NMDA generalization curve. 
   
Cross generalization 
 Cross generalization testing was then completed for both CLZ-trained mice (Fig. 5) 
and NMDA-trained mice (Fig. 6).  The NMDA dose response curve was completed by 
nine CLZ-trained animals as one animal was removed due to illness. NMDA failed to 
produce either full or partial substitution at any dose in the CLZ-trained mice with the 56 
mg/kg dose producing a maximum of 25.08% DLR. The two highest doses tested (30 and 
56 mg/kg) both engendered significant rate suppression (F
5, 53 
= 9.47, p < 0.0001).  
The CLZ dose response curve was completed by nine NMDA-trained mice, as two 
of the NMDA mice were removed from the study because of illness. An intermediate dose 
of CLZ (0.625 mg/kg) produced partial substitution (61.72% DLR). Significant rate 
suppression occurred at the 5.0 mg/kg dose of CLZ (F
7, 95 
= 11.87, p < 0.0001). 
Combination Testing  
 Combination testing was conducted to see if either drug could potentiate the 
discriminative stimulus effects of the other.  A low non-generalizing dose of CLZ 0.625 
mg/kg was given in combination with the range of NMDA doses (Fig. 7) to nine CLZ 
trained mice, producing both partial substitution and full substitution. The 0.625 mg/kg 
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dose of CLZ produced a maximum of 33.03 % DLR when administered alone during the 
initial generalization curve, this increased slightly (45.09%) when administered with VEH 
in the combination curve.  As the dose of NMDA given with the 0.625 mg/kg CLZ 
increased the %DLR increased.  The combination of 0.625 mg/kg CLZ + 30 mg/kg 
NMDA achieved partial substitution (61.82% DLR) and with the combination dose of 
0.625 mg/kg CLZ + 56 mg/kg NDMA full substitution (92.82% DLR) occurred. 
Significant rate suppression (F
6, 62 
= 3.18, p = 0.0104) was produced by the 56 mg/kg 
NMDA + 0.625 mg/kg CLZ combination dose although all animals responded. The ED50 
calculated for this combination curve was 5.66 mg/kg NMDA + 0.625 mg/kg CLZ (95% 
C.I. = 2.15-14.89 mg/kg).  
A low, non-generalizing dose of NMDA (10mg/kg) was given to eight NDMA 
trained mice in combination with the range of CLZ doses (Fig. 8). The 10 mg/kg dose 
produced a maximum of 31.56 %DLR when given to the NMDA-trained animals alone. 
When given in combination with the CLZ the %DLR increased as the CLZ dose increased, 
full substitution occurred in the 10 mg/kg NMDA + 2.5 mg/kg CLZ (80.04% DLR) and for 
the 10 mg/kg NMDA + 5.0 mg/kg CLZ (100% DLR) dose combinations. Rate suppression 
was significant at the 10 mg/kg NMDA + 5.0 mg/kg CLZ combination with only a single 
animal responding (F
6, 55 
= 24.46, p < 0.0001). The ED50 calculated for the combination 
curve was 0.76 mg/kg CLZ +10 mg/kg NMDA (95% C.I. = 0.37-1.58 mg/kg). 
Prazosin Generalization  
 The prazosin dose response curve for the CLZ-trained animals is presented in 
Figure 9. All nine of the CLZ-trained mice completed prazosin testing. Prazosin produced 
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full substitution for CLZ at a dose of 3.0 mg/kg (92.20% DLR). Significant rate 
suppression was observed at both the 1.73 mg/kg and 3.0 mg/kg doses (F
6, 62 
= 7.64, p < 
0.0001). The prazosin ED50 in CLZ-trained animals was 1.50 mg/kg (95% C.I. =1.21-1.87 
mg/kg).  
The prazosin dose response curve for the NMDA-trained animals is presented in 
Figure 10 and included five mice. One animal became ill and did not complete testing for 
one dose (as noted in Fig. 10 legend). Very high partial substitution (79.16% DLR) was 
achieved at the 0.3 mg/kg PRZ dose. Full substitution was achieved at the 1.0 mg/kg 
(98.77% DLR) and 3.0 mg/kg (99.62% DLR) PRZ doses. No significant rate suppression 
occurred at any of the tested doses of prazosin. Prazosin produced an ED50 = 0.67 mg/kg 
(95% C.I. = 0.025-1.78 mg/kg) in the NMDA-trained mice.  




































 Figure 1. Acquisition of Clozapine Discrimination  
Figure 1. Acquisition of two-lever drug discrimination for the 2.5 mg/kg clozapine training 
dose is shown. The mean percentage of drug lever responding (+ SEM) is presented for 
both drug injection (filled circles) and for vehicle injection (open circles). The area below 
the dashed line at 20% indicates vehicle appropriate responding and the area above the 
dashed line at 80% indicates drug appropriate responding. Animals that had achieved 
criteria were removed from the plot as indicated by the numbers in parenthesis.  
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 Figure 2. Acquisition of NMDA Discrimination  
Figure 2. Acquisition of two-lever drug discrimination for the 30 mg/kg NMDA training 
dose is shown. The mean percentage of drug lever responding (+ SEM) is presented for 
both drug injection (filled circles) and for vehicle injection (open circles). The area below 
the dashed line at 20% indicates vehicle appropriate responding and the area above the 
dashed line at 80% indicates drug appropriate responding. Animals that had achieved 
criteria were removed from the plot as indicated by the numbers in parenthesis.  
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Figure 3. Clozapine Generalization Graph 
Figure 3. The generalization data for the clozapine 2.5 mg/kg training dose curve is shown 
including mean percentage (+ SEM) drug-lever responding (filled circles) and the mean (+ 
SEM) responses per minute (open circles).  The dashed line at 80% indicates full 
generalization to the training drug. Prior to testing control test sessions were conducted for 
both clozapine and vehicle. Mice with response rates of lower than two responses per 
minute were not included in the percentage drug lever responding. Significant decreases in 
response rate are noted by asterisks (* p<0.05, ** p<0.01). 
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Figure 4. NMDA Generalization Graph  
Figure 4. The generalization data for the NMDA 30 mg/kg training dose curve is shown 
including mean percentage (+ SEM) drug-lever responding (filled circles) and the mean (+ 
SEM) responses per minute (open circles).  The dashed line at 80% indicates full 
generalization to the training drug. Prior to testing control test sessions were conducted for 
both clozapine and vehicle. Mice with response rates of lower than two responses per 
minute were not included in the percentage drug lever responding. Significant decreases in 
response rate are noted by asterisks (* p<0.05, ** p<0.01). 




































Figure 5. Clozapine Cross-generalization With NMDA  
Figure 5. The cross-generalization data for the clozapine 2.5 mg/kg trained animals 
NMDA dose curve is shown including mean percentage (+ SEM) drug-lever responding 
(filled circles) and the mean (+ SEM) responses per minute (open circles).  The dashed 
line at 80% indicates full generalization to the training drug. Prior to testing control test 
sessions were conducted for both clozapine and vehicle. Mice with response rates of lower 
than two responses per minute were not included in the percentage drug lever responding. 
Significant decreases in response rate are noted by asterisks (* p<0.05, ** p<0.01). 
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 Figure 6. NMDA Cross-generalization With Clozapine  
Figure 6. The cross-generalization data for the 30 mg/kg trained animals clozapine dose 
curve is shown including mean percentage (+ SEM) drug-lever responding (filled circles) 
and the mean (+ SEM) responses per minute (open circles).  The dashed line at 80% 
indicates full generalization to the training drug. Prior to testing control test sessions were 
conducted for both clozapine and vehicle. Mice with response rates of lower than two 
responses per minute were not included in the percentage drug lever responding. 
Significant decreases in response rate are noted by asterisks (* p<0.05, ** p<0.01). 
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Figure 7.  Low Dose Clozapine In Combination With NMDA  
Figure 7. The generalization data for the 2.5 mg/kg CLZ trained animals given 0.625 
mg/kg CLZ in addition to NMDA is shown including mean percentage (+ SEM) drug-lever 
responding (filled circles) and the mean (+ SEM) responses per minute (open circles).  The 
dashed line at 80% indicates full generalization to the training drug. Prior to testing control 
test sessions were conducted for both clozapine and vehicle. Mice with response rates of 
lower than two responses per minute were not included in the percentage drug lever 
responding. Significant decreases in response rate are noted by asterisks (* p<0.05, ** 
p<0.01). 
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Figure 8.  Low Dose NMDA In Combination With Clozapine 
Figure 8. The generalization data for the 30 mg/kg NDMA trained animals given 10 mg/kg 
NDMA in addition to CLZ is shown including mean percentage (+ SEM) drug-lever 
responding (filled circles) and the mean (+ SEM) responses per minute (open circles).  The 
dashed line at 80% indicates full generalization to the training drug. Prior to testing control 
test sessions were conducted for both clozapine and vehicle. Mice with response rates of 
lower than two responses per minute were not included in the percentage drug lever 
responding. Significant decreases in response rate are noted by asterisks (* p<0.05, ** 
p<0.01). 
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Figure 9.  Prazosin Generalization In Clozapine Trained Animals 
Figure 9. The Prazosin generalization data for the 2.5 mg/kg CLZ trained animals is shown 
including mean percentage (+ SEM) drug-lever responding (filled circles) and the mean (+ 
SEM) responses per minute (open circles).  The dashed line at 80% indicates full 
generalization to the training drug. Prior to testing control test sessions were conducted for 
both clozapine and vehicle. Mice with response rates of lower than two responses per 
minute were not included in the percentage drug lever responding. Significant decreases in 
response rate are noted by asterisks (* p<0.05, ** p<0.01). 




































Figure 10.  Prazosin Generalization In NMDA Trained Animals 
Figure 10. The Prazosin generalization data for the 30 mg/kg NMDA trained animals is 
shown including mean percentage (+ SEM) drug-lever responding (filled circles) and the 
mean (+ SEM) responses per minute (open circles).  The dashed line at 80% indicates full 
generalization to the training drug. Prior to testing control test sessions were conducted for 
both clozapine and vehicle. Mice with response rates of lower than two responses per 
minute were not included in the percentage drug lever responding. Significant decreases in 
response rate are noted by asterisks (* p<0.05, ** p<0.01). 
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 The current study replicates previous findings from this lab that clozapine has a 
robust and reliably trainable discriminative stimulus. The majority of C57BL/6 mice 
successfully reached criteria (10 of 12) at the training dose of 2.5 mg/kg. The average 
number of sessions until clozapine-trained animals met criteria was 25.2 with a range of 
10-39 sessions, which was consistent with  previous studies from our lab in which 
C57BL/6 mice reached training criteria in an average of 35.6 sessions with a range of 15-
52 sessions (Philibin et al., 2009) or 14.8 sessions with a range of 6-34 sessions (Philibin et 
al., 2009). The generalization results in the present study for clozapine were also similar to 
previous studies completed in this lab with an ED50 = 0.92 mg/kg (95% C.I. = 0.66-1.29 
mg/kg), which was slightly lower than the earlier cohorts of clozapine trained mice with 
ED50s of 1.14 mg/kg and 1.19 mg/kg, respectively (Philibin et al., 2005; Philibin et al., 
2009). The two highest doses (2.5 and 5.0 mg/kg) of clozapine administered produced full 
generalization.  
 The current study also showed that NMDA has a sufficiently robust discriminative 
stimulus to successfully establish two-lever drug discrimination in C57BL/6 mice at 30 
mg/kg.  The complete group of 12 C57BL/6 mice successfully reached criteria at the 
training dose 30 mg/kg. The average number of sessions to reach training criteria was 27.3 
with a range of 14-56 sessions. The generalization results for NMDA-trained C57BL/6 
mice were similar to NMDA-trained rats in the number of sessions required to reach 
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criteria (M=30) but they had a much lower ED50 = 10.8 mg/kg (95%C.I= 7.69-15.16 
mg/kg) as compared to rats ED50 = 17.1 (Willetts & Balster, 1989). The two highest doses 
(30 and 56 mg/kg) of NMDA produced full generalization. The number of sessions to 
reach criteria did not differ significantly between the two training drugs, clozapine and 
NMDA. 
  When cross-generalization testing was completed, an asymmetrical relationship 
between the two training drugs was revealed. In the clozapine-trained animals NMDA 
failed to produce clozapine-appropriate responding more than 25% of the time even at 
doses that produced significant rate suppression. In the NMDA-trained animals, however, 
clozapine produced partial substitution (above 60%) at the 0.625 mg/kg dose. This 
demonstrated an asymmetrical relationship between clozapine and NMDA in terms of their 
discriminative stimuli.  
 In subsequent testing, a low, non-generalizing dose of clozapine (0.625 mg/kg) was 
administered in combination with NMDA in the clozapine-trained animals to evaluate if 
this combination would result in a dose dependant shift of the curve.  The combination 
testing produced a leftward shift in the curve. The highest drug lever responding 
engendered by the 0.625 mg/kg dose of clozapine when administered alone was only 33%; 
however, in combination with doses of NMDA the drug lever responding increased and 
with the two highest doses partial (61.82%) and full substitution (92.82%) for clozapine 
was achieved 
 A similar leftward shift was obtained in the NMDA-trained animals with the 
combination of a low dose of NMDA plus several clozapine doses. The non-generalizing 
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dose (10 mg/kg) of NMDA produced only 31% NMDA-lever responding when 
administered alone, but in combination with doses of clozapine the NMDA-lever 
responding increased at all doses and full substitution (80% and 100%) was obtained at the 
two highest doses of clozapine (2.5 and 5.0 mg/kg). This potentiation of the NMDA 
discriminative stimulus provides further evidence of the interaction of these two drugs 
through some intermediate action as there is no evidence that clozapine acts directly on the 
NMDA receptor complex.  
 Interestingly, the α1 adrenoreceptor antagonist prazosin produced full substitution 
in both the clozapine- and the NMDA-trained animals. The intermediate dose (1.0 mg/kg) 
produced full substitution in the NMDA-trained animals, while the high dose of prazosin 
(3.0 mg/kg) produced full substitution in both NMDA-trained and clozapine-trained 
animals. This replicates findings from our lab that 2.8 mg/kg prazosin fully substitutes for 
2.5 mg/kg clozapine in C57BL/6 mice (Philibin et al., 2009). These results also are similar 
to previous findings in 30 mg/kg NMDA-trained rats in which the α1 adrenoreceptor 
antagonists prazosin and WB4101 fully substituted for NMDA (Arnt, Sanchez, Lenz, 
Madsen, & Krogsgaard-Larsen, 1997).  
 Clozapine has a complex receptor profile that has actions at serotonergic, 
dopaminergic, adrenergic, cholinergic, and histaminergic receptors. Previous research 
regarding the discriminative stimulus properties of clozapine in C57BL/6 mice has 
revealed that antagonism of serotonergic receptors and α1 adrenoreceptors is an important 
part of clozapine’s discriminative stimulus cue (Philibin et al., 2009). When tested in 
NMDA-trained C57BL/6 mice, the α1 adrenoreceptor antagonist prazosin fully substituted 
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for NMDA. In previous research in rats the antipsychotic spiperone, which has 
serotonergic and dopaminergic activity, also fully substituted for NMDA (Cory-Slechta et 
al., 1996).  This indicates that although NMDA is a specific agonist at its endogenous site 
on the NMDA receptor, activation of other receptors can mimic the subjective effects of 
NMDA in the drug discrimination procedure.  
This relationship may be due to an interaction between NMDA, serotonin and α1 
adrenoreceptor systems. It has been shown that systemic administration of phencyclidine 
and ketamine (non-competitive NMDA antagonists) increases serotonin efflux in the 
medial prefrontal cortex of rats. Blockade of this enhanced serotonin efflux was achieved 
by the atypical antipsychotics clozapine and olanzapine and by prazosin, but not by 
haloperidol (Amargos-Bosch, Lopez-Gil, Artigas, & Adell, 2006).  Serotonin efflux 
resulting from microdialysis of cirazoline, an α1 adrenoreceptor agonist, in the medial 
prefrontal cortex can be reversed by clozapine, olanzapine and prazosin and by the typical 
antipsychotics chlorpromazine and haloperidol (Amargos-Bosch, Adell, Bortolozzi, & 
Artigas, 2003). This suggests that α1 adrenoreceptor activity results in modulation of 
serotonin in the medial prefrontal cortex of rats whether induced by serotonin agonists or 
NMDA antagonists, and may be part of the therapeutic action of clozapine.  
Additional aspects of clozapine that are of interest in its relationship to NMDA 
involve dopamine functioning in response to adrenergic and NMDA receptor actions.  
Clozapine’s unique efficacy in refractory patients, cognitive improvement, and reduction 
of suicidality has been argued to be due to its higher ratio of serotonin vs. dopamine 
occupancy (Meltzer et al., 1989b; Meltzer & McGurk, 1999; Meltzer et al., 1996). Current 
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research suggests that while that ratio is important, adrenergic action should also be 
studied further as a possible component of clozapine’s therapeutic action. The α1 
adrenoreceptor antagonist prazosin and the α2 adrenoreceptor antagonist idazoxan when 
administered with D2 antagonists or haloperidol in a condition avoidance paradigm (CAR) 
significantly enhanced the suppression of CAR activity without increasing catalepsy in the 
D2 antagonists and decreased catalepsy significantly with haloperidol (Svensson, 2000; 
Wadenberg, Wiker, & Svensson, 2007). Prazosin also stimulates dopamine neurons in the 
ventral tegmental area (VTA) of rats but suppresses activation of mesolimbic sub-cortical 
DA neurons (Svensson, 2000, 2003).  These findings suggest that α1 adrenoreceptor 
antagonists may modulate dopaminergic function in certain brain areas, one of the key 
functions of antipsychotic drugs. However, there are many other receptors and 
neurotransmitter systems that are activated by the administration of clozapine (muscarinic, 
histaminergic, etc.) and their contributions to the therapeutic effects of the drug are not yet 
fully understood.  
 Recent attention in treatment development and genetic modeling in schizophrenia 
research has focused on the glycine-binding site of the NMDA receptor complex. Glycine 
site agonists D-serine, D-alanine and glycine have repeatedly been shown to improve 
negative symptoms. However, when administered with clozapine (which is known to show 
clinical improvement of negative symptoms), they do not show statistically increased 
effectiveness on negative symptoms (Shim, Hammonds, & Kee, 2008).  This suggests that 
the receptor action produced by administration of these drugs may already be present in the 
complex receptor actions of clozapine. Glycine site activation also has been shown to  
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improve cognition in several animal models (Andersen & Pouzet, 2004; Shim et al., 2008). 
Genetically induced reduction in NMDA receptor glycine affinity in C57BL/6 mice 
produces GRIND481N mice (Labrie, Lipina, & Roder, 2008) and these genetically modified 
mice show unusually prolonged latent inhibition, deficits in social approach, and reduced 
reactivity to spatial change. In these mice used to model the negative and cognitive 
symptoms present in schizophrenia, treatment with D-serine and clozapine reversed the 
abnormalities (Labrie et al., 2008). This finding suggests a role for the glycine site both in 
regard to the symptoms of schizophrenia and to the functionality of clozapine and also 
suggests that glycine agonists may have therapeutic efficacy for the treatment of 
schizophrenia.  
 The glycine site also is important as it may be the actual site of clozapine’s action 
on the NMDA receptor complex.  Some recent in vivo electrophysiological data suggests 
that clozapine’s activation of dopamine neurons in the VTA of rats depends on the level of 
endogenous kynurenic acid, an NMDA glycine site antagonist (Schwieler, Linderholm, 
Nilsson-Todd, Erhardt, & Engberg, 2008). Clozapine given intravenously increased the 
firing of dopamine neurons in the VTA unless rats were treated with indomethicin, a cox1 
inhibitor that increased brain levels of endogenous kynurenic acid. When rats were treated 
with indomethicin, clozapine’s excitatory action was reversed into an inhibitory one. 
Conversely, when a cox2 inhibitor was given and kynurenic acid levels decreased, the 
excitatory action of clozapine was potentiated (Schwieler et al., 2008).  Further, the 
activation of dopamine neurons by clozapine mirrors the activation seen after 
administration of L-701,324, a site specific glycine antagonist, or by increased levels of 
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kynurenic acid (Erhardt & Engberg, 2002; Schwieler, Engberg, & Erhardt, 2004). This 
may signify that although clozapine has D2 receptor affinity (though lower than typical 
antipsychotics) its actions on dopaminergic neurons in some brain areas are through 
modulation of the glutamate system via NMDA receptor activity.  
 In the current study clozapine produced partial substitution in NMDA-trained 
animals when administered alone. Clozapine’s diverse receptor binding profile suggests 
that actions at one or more receptor sites may contribute to this partial substitution (i.e., at 
5HT2A receptors, action at α1 adrenoreceptors, and indirect action at the NMDA glycine 
receptor site). Also, the fact that clozapine binds to receptors that have been shown to 
interact with NMDA suggests that it may be activity at one or more of these receptors that 
prevented clozapine from fully substituting for NMDA. NMDA also failed to substitute in 
the clozapine-trained mice, illustrating that agonism at the glutamate site is insufficient to 
mimic the complex cue of clozapine. Further study with other select ligands is needed to 
investigate these complex relationships.  
The α1 adrenoreceptor antagonist prazosin also achieved full substitution in both 
training groups. This replicates previous research in C57BL/6 mice trained to discriminate 
clozapine (Philibin et al., 2009), and replicates previous research in rats trained to 
discriminate NMDA (Arnt, 1997). Thus, clozapine’s complex cue in C57BL/6 mice 
appears to be partially mediated by α1 adrenoreceptor antagonism. Similarly, NMDA also 
appears to have a compound discriminative stimulus that includes antagonism at α1 
adrenoreceptors.   
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Serotonergic antagonism, specifically at 5HT2A receptors, has been shown 
previously in clozapine-trained C57BL/6 mice to be a significant part of clozapine’s cue as 
the antagonist ritanserin fully substituted for clozapine (Philibin et al., 2009). Previous 
research in NMDA-trained rats has shown that the antipsychotic spiperone, which has 
antagonistic activity at 5HT2A and at D2, fully substitutes for NMDA. This additional 
similarity has not yet been explored in C57BL/6 mice and it would be of interest to 
investigate whether this similarity is shared in mice, as well as rats, by testing ritanserin in 
NMDA-trained mice.  
The modulating effect of kynurenic acid on the activation of dopamine by 
clozapine is also of interest. It would be interesting to see if clozapine’s complex cue can 
be blocked by the administration of glycine site agonists. It would also be of interest to 
investigate whether site specific agonists substitute for NMDA’s discriminative cue, even 
thought they have different activation sites on the NMDA receptor complex. Since NMDA 
antagonists PCP and Ketamine produce psychotic-like symptoms in humans, the effects of 
NMDA antagonists on clozapine’s cue would also be of interest.  
In human trials the results of adjunctive treatment with NMDA agonists have had 
mixed results. Treatment with moderate doses of D-serine (30mg/kg/ day) combined with 
typical antipsychotics improved negative and, to a lesser degree, positive and cognitive 
symptoms without an increase in side effects (G. Tsai, Yang, Chung, Lange, & Coyle, 
1998). However, when given in conjunction with clozapine there was no increase in 
therapeutic  effect (G. E. Tsai et al., 1999). Use of other agonists at the glycine site like D-
cycloserine worsened negative symptoms when given with clozapine (Goff et al., 1999; 
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Javitt, 2002). The mixed results of glycine site modulators in clinical application 
underlines the importance of a greater preclinical knowledge of the interactions between 
the NMDA receptor and clozapine.  
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